Background

WHIM syndrome is a rare, autosomal dominant immunodeficiency characterized by Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. It is caused by gain-of-function mutations in the chemokine receptor CXCR4, where truncation of the C-terminus leads to receptor overactivation and excessive retention of leukocytes in the bone marrow. This results in chronic reduction of neutrophils, lymphocytes, and monocytes in the peripheral blood, leaving patients susceptible to bacterial infections and HPV-related warts.

Existing treatments have relied on intravenous immunoglobulin (IVIG) and granulocyte colony-stimulating factor (G-CSF) administration, but with limited efficacy and significant burden of administration. Mavorixafor, an oral CXCR4 antagonist approved by the FDA in 2024, represents the first targeted therapy, but does not correct the underlying genetic defect. In contrast, a case report of a "WHIM-09" patient published in Cell in 2015 suggested a different possibility. This patient experienced a large deletion (chromothripsis) of chromosome 2 in one of their hematopoietic stem cells (HSCs), resulting in complete deletion of the mutant CXCR4^R334X^ allele, and subsequent reconstitution of the entire hematopoietic system with this HSC, leading to sustained remission for over 20 years.

Key Findings

The current correspondence, published in the July 2026 issue of New England Journal of Medicine, reports a second case of spontaneous somatic genetic correction reversing WHIM syndrome. This patient, described by the Philip M. Murphy group at the NIH National Institute of Allergy and Infectious Diseases (NIAID), had typical WHIM syndrome due to CXCR4 overactivation and experienced splenic rupture. Subsequently, the patient entered sustained remission, and genomic analysis revealed that a somatic mutation had created CXCR4 haploinsufficiency.

This finding is notable because of the mechanistic difference. The 2015 WHIM-09 case involved a single, dramatic event of chromothripsis that deleted 164 genes, whereas in this patient, a more localized somatic mutation achieved the same result—silencing of the mutant allele. Both cases demonstrate that HSCs with CXCR4 haploinsufficiency have a strong competitive advantage for engraftment compared to normal or mutant HSCs. Indeed, in a mouse bone marrow transplantation experiment, CXCR4 haploinsufficient donor bone marrow showed superior long-term engraftment compared to wild-type and WHIM model bone marrow, even without bone marrow conditioning.

Significance and Outlook

The fact that somatic genetic correction via different pathways independently induced remission in the same disease strongly supports the notion that silencing of the CXCR4 allele is a valid therapeutic strategy for WHIM syndrome. A plausible approach involves inactivating one copy of the mutant CXCR4 in the patient's own HSCs using CRISPR-based gene editing or base editing, followed by autologous transplantation without bone marrow conditioning. Because CXCR4 haploinsufficient cells have intrinsic engraftment advantages, only a small number of corrected HSCs may be needed to gradually replace the bone marrow.

However, challenges remain. This report is a single-patient correspondence, and the exact type and timing of the somatic mutation, as well as the causal relationship with splenic rupture, have not been fully elucidated. The long-term effects of CXCR4 haploinsufficiency on other immune functions also need to be investigated, and clinical application of gene editing requires prior validation of off-target effects and editing efficiency. Nevertheless, the fact that nature has provided the same solution twice elevates the plausibility of this strategy beyond mere chance and into the realm of biological principle.